Introduction
The biopharma, cell and gene therapy, and synthetic biology industries have already recognized the potential of high-throughput automated methodologies to accelerate process development. These methodologies are well-established, particularly in drug discovery and cell line development. However, a significant bottleneck persists in process development because current small-scale high-throughput bioreactor systems fall short in key areas such as customizable automation, advanced digitalization, seamless integration of online PAT for CPP and CQA analysis, and the ability to incorporate DSP operations. Additionally, the high costs of many of these systems limit their accessibility to a broader range of users.
In this webinar, Securecell’s CEO and Head of Innovation, Carlo Andretta, will unveil the Integra1 64, a cutting-edge high-throughput bioprocessing system. This platform is designed to fully automate process development, addressing the key limitations of current technologies and setting a new standard for efficiency and innovation in the field.
If you are already heavily invested in a high-throughput bioreactor solution, an alternative disruptive technology, the SampleBus, will be introduced, integrating existing high-throughput installations into an advanced automation workflow.
Join our webinar and prepare for one of the most groundbreaking transformations in process development!
This webinar meets two times, please join based on your availability.
Tue, October 15, 2024, 09:00 - 10:00 am CET
Tue, October 15, 2024, 05:00 - 06:00 am CET
Duration: 50 min (content) + 10 min (Q&A)
